EN DE
Watch Ziyuanyuan Holdings Group for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Ziyuanyuan Holdings Group (8223) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Ziyuanyuan Holdings Group stock HK$0.29, price HK$0.27, upside +9.3%, quality 38 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China · ISIN KYG9898B1041

ZH Ziyuanyuan Holdings Group logo Thin data Nov 10, 2026

Ziyuanyuan Holdings Group

8223 · HK

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Fair value HK$0.2897 · Fairly valued 
Expensive Growth (revenue 5y +53.8 %/yr in CNY) 
Mixed vs. peers (5/11) 
Revenue last quarter 56% below a year ago. 
Quality 38/100 
Falling price (downtrend) 
Loss-making · -3.2% net margin (TTM) 
Negative free cash flow 
Narrow moat 15/100 · thin data
Thin data 
Estimate
Watch Ziyuanyuan Holdings Group for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$2.78 HK$0.1030 Fair Value HK$0.2897 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range HK$0.1030 – HK$2.78 · fair‑value band HK$0.2172 – HK$0.3621 · the HK$0.2650 price screens below the HK$0.2897 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Ziyuanyuan Holdings in your weekly email

Every Wednesday you see whether Ziyuanyuan Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Ziyuanyuan Holdings Group Limited, an investment holding company, provides medical equipment finance leasing services in the People's Republic of China. The company operates through Finance Leasing Service, Postpartum Care Service, Trading Business, and Other segments.

Show moreShow less

It offers direct finance leasing and sale-leaseback services. The company also provides maternal and child postpartum care services; IT services; and technological services.

In addition, it trades in medical equipment and consumables, such as dental, maternal and child, and large hospital medical equipment, as well as aesthetic medicine. The company was founded in 2014 and is based in Shenzhen, the People's Republic of China.

Ziyuanyuan Holdings Group Limited is a subsidiary of Hero Global Limited.

Stock analysis

Ziyuanyuan Holdings Group (8223) currently trades at HK$0.2650, while our estimate is HK$0.2897, so the stock looks roughly fairly valued today (gap 8.5%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$0.2172 (bear) to HK$0.3621 (bull), the price of HK$0.2650 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Ziyuanyuan Holdings Group reported revenue of 503M CNY in FY2025 versus 119M CNY in FY2021, a compound +43.3%/yr. Reported net income was −10.4M CNY in FY2025.

Key figures

Market cap HK$137M (≈ $17.4M) Micro · P/S ratio 0.39 · Net margin −2.1% · Return on equity −3.7% · Return on assets (EBIT) 3.3% (5-year average) · Operating margin 8.1% · Revenue (TTM) 366M CNY · Revenue growth (YoY) −55.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (low confidence).

What moves the price

The share trades about 69% below its 52-week high and 157% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 38% fair-value upside, at 9%, 8223 screens richer than that median.

Fair Value

Bear HK$0.2172 Fair Value HK$0.2897 Bull HK$0.3621
Price HK$0.2650 · Upside +9.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 15
How much profit the company makes from its sales and capital
Quality Growth 49
Are margins and returns getting better?
Cashflow 50
Do the profits arrive as real cash?
Financial strength 43
Debt, balance sheet and risk of trouble
Investment 83
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 33
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 11
Distance to the 52-week high, does not count
New shares 14
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−8.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+53.8%
Start year 2020 (pandemic). Over 10 years: +46.8% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+46.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
29.3% (2020) → 3.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 8223, get fair value alerts →

Compare Ziyuanyuan Holdings Group with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 81 stocks

Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 38 · Bottom 25%
Fair Value upside +9.3% · Above median
Profitability
Return on assets −1.3% · Bottom 25%
Net margin (12 months) −3.2% · Bottom 25%
Operating margin (12 months) 8.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −55.6% · Bottom 25%
Balance sheet
Debt / equity 0.15× · Above median

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/B 0.39× · Cheapest 25%
P/S (12 months) 0.32× · Cheaper than median
EV/EBITDA 7.6× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)46 · sector 37
FUTURE (revenue growth)0 · sector 18
PAST (return on equity)0 · sector 25
HEALTH (low debt)92 · sector 96
DIVIDEND (yield)0 · sector 54

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Sinopharm Group 1099 HK$16.67 HK$50.01 +200% vs 8223
Jointown Pharmaceutical Group 600998 ¥5.09 ¥11.56 +127% vs 8223
Shanghai Pharmaceuticals Holding 601607 ¥16.13 ¥35.78 +122% vs 8223
China National Medicines Corporation 600511 ¥28.38 ¥58.47 +106% vs 8223
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥19.35 ¥26.64 +38% vs 8223
Cencora, Inc COR $359.03 $341.58 −5% vs 8223
Henry Schein, Inc HSIC $86.22 $78.69 −9% vs 8223
McKesson Corporation MCK $1,103 $822.74 −25% vs 8223
Galenica AG GALE CHF 91.20 CHF 61.79 −32% vs 8223
Cardinal Health, Inc CAH $281.10 $163.14 −42% vs 8223

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Ziyuanyuan Holdings Group: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Ziyuanyuan Holdings Group Fair Value". https://www.fairvalue-calculator.com/stock/8223

Frequently asked questions

Is Ziyuanyuan Holdings Group (8223) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is HK$0.2897 versus a price of HK$0.2650, about +9% upside (fairly valued).
What is the fair value of 8223?
Our estimate for Ziyuanyuan Holdings Group is HK$0.2897 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$0.2650.
What is the quality score of 8223?
Ziyuanyuan Holdings Group has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ziyuanyuan Holdings Group (8223)?
Our calculated price target is the estimate of HK$0.2897 (as of Nov 10, 2026). Cautious scenario HK$0.2172, optimistic scenario HK$0.3621. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Ziyuanyuan Holdings Group stock forecast for 2026?
Our estimate puts fair value at HK$0.2897, about +9% upside versus a price of HK$0.2650 (fairly valued). Cautious scenario HK$0.2172, optimistic scenario HK$0.3621. The calculation is refreshed regularly with new filings.
What is the revenue of Ziyuanyuan Holdings Group (8223)?
Ziyuanyuan Holdings Group reported trailing-twelve-month revenue of about 366M CNY (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Ziyuanyuan Holdings Group (8223)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ziyuanyuan Holdings Group it is HK$0.2897 per share (as of Nov 10, 2026), against a price of HK$0.2650.
Is Ziyuanyuan Holdings Group stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 8223 trades below its calculated fair value: price HK$0.2650, fair value HK$0.2897, a gap of about +9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 8223?
No. The price is what the market pays today (HK$0.2650); the fair value is what the company's own numbers justify (HK$0.2897). For Ziyuanyuan Holdings Group the two are HK$0.0247 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ziyuanyuan Holdings Group worth?
The market values Ziyuanyuan Holdings Group at about HK$137M (market capitalisation, as of Nov 10, 2026). Per share that is HK$0.2650; our models calculate a fair value of HK$0.2897 per share.
What do the bullish and bearish scenarios say about 8223?
Our models span a range for Ziyuanyuan Holdings Group: cautious scenario HK$0.2172, base HK$0.2897, optimistic HK$0.3621 per share (as of Nov 10, 2026, price HK$0.2650). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ziyuanyuan Holdings Group (8223)?
Balance-sheet figures for Ziyuanyuan Holdings Group (as of Nov 10, 2026): return on equity −3.7%, debt of 0.15 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is 8223 from its 52-week high?
Ziyuanyuan Holdings Group trades at HK$0.2650, about 69% below its 52-week high of HK$0.8500 and 157% above the low of HK$0.1030 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.2897 is for.
Which stocks are comparable to Ziyuanyuan Holdings Group?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ziyuanyuan Holdings Group stock attractive at the current price?
The data as of Nov 10, 2026: price HK$0.2650, calculated fair value HK$0.2897 (+9%), Quality Score 38/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Ziyuanyuan Holdings Group currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ziyuanyuan Holdings Group (8223)?
The closing price on Nov 13, 2026 was HK$0.2650. Our estimate is HK$0.2897, about +9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ziyuanyuan Holdings Group right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Ziyuanyuan Holdings Group

How large is the market capitalisation of Ziyuanyuan Holdings Group (8223)?
The market capitalisation of Ziyuanyuan Holdings Group is HK$137M (≈ $17.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ziyuanyuan Holdings Group (8223)?
The price-to-sales ratio of Ziyuanyuan Holdings Group is 0.39 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Ziyuanyuan Holdings Group (8223)?
The net margin of Ziyuanyuan Holdings Group is −2.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ziyuanyuan Holdings Group (8223)?
The return on equity (ROE) of Ziyuanyuan Holdings Group is −3.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ziyuanyuan Holdings Group (8223)?
On an EBIT basis the return on assets of Ziyuanyuan Holdings Group is 3.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ziyuanyuan Holdings Group (8223)?
The operating margin of Ziyuanyuan Holdings Group is 8.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ziyuanyuan Holdings Group (8223)?
Revenue at Ziyuanyuan Holdings Group is down 55.6% versus a year earlier (3y avg +15.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ziyuanyuan Holdings Group (8223)?
Earnings per share at Ziyuanyuan Holdings Group are down 21.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Ziyuanyuan Holdings Group (8223) generate?
The free cash flow of Ziyuanyuan Holdings Group is −36.3M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Ziyuanyuan Holdings Group (8223) carry?
The net debt of Ziyuanyuan Holdings Group is 228M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Ziyuanyuan Holdings Group in the live analysis

One click puts Ziyuanyuan Holdings Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.